Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 3/20 | 0.40 |
| ▸ | MMP3 | P08254 | 3/20 | 0.40 |
| ▸ | MMP9 | P14780 | 3/20 | 0.40 |
| ▸ | MMP13 | P45452 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376741 | 1.00 | MAOA (0.50) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL1540828 | 0.85 | MAOA (0.45) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL19144898 | 0.85 | MAOA (0.47) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL1540432 | 0.85 | MAOA (0.51) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL10175212 | 0.83 | MTNR1A (0.50) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL376564 | 0.82 | MAOA (0.45) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL10175128 | 0.82 | MAOA (0.55) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL25236742 | 0.82 | MAOA (0.53) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL25274884 | 0.82 | MAOA (0.53) | MAOAMAOBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL1540560 | 0.81 | MTNR1A (0.45) | MAOAMAOBMTNR1AMTNR1BFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3095784-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9493431-B2 | Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2387559-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20160002187-A1 | APOPTOSIS-INDUCING AGENT FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-01-07 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9156856-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| US-20130184278-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2013-07-18 | — | — | US | disclosed |
| US-8338466-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| EP-2387559-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20100184766-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010083442-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2009036035-A1 | BCL-2 INHIBITORS | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | MAOA 2934/4885MAOB 2914/4885MTNR1A 3457/4885 |
| US-20100184766-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MAOA 4356/4885MAOB 3866/4885MTNR1A 3900/4885 |
| US-20160002187-A1 | APOPTOSIS-INDUCING AGENT FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MAOA 4366/4885MAOB 4000/4885MTNR1A 3932/4885 |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | MAOA 1944/4885MAOB 811/4885MTNR1A 2899/4885 |
| US-20130184278-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MAOA 4356/4885MAOB 3866/4885MTNR1A 3900/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | MAOA 1944/4885MAOB 811/4885MTNR1A 2899/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | MAOA 1944/4885MAOB 811/4885MTNR1A 2899/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | MAOA 3289/4885MAOB 1743/4885MTNR1A 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.